Shumei Kato

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 25

Top Topics

Peritoneal Dialysis

Metastatic Colorectal Cancer

Circulating Tumor

Top Venues

JCO precision oncology

Cancer research communications

Molecular oncology

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase 1 Study of KIN-3248, an irreversible small molecule pan-FGFR inhibitor, in Patients with Advanced FGFR 2/3 Driven Solid Tumors. Cancer research communications (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do Youn Oh, Paul Severson, Betty Y Tam, Cheng S Quah, James J Harding
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors. Cancer research communications 4 (4) (2024)
Shai Rosenberg, Gil Ben Cohen, Shumei Kato, Ryosuke Okamura, Scott M Lippman, Razelle Kurzrock
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. Molecular oncology (2023)
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K Nesline, Jeffrey M Conroy, Eitan Rubin, Ramez N Eskander, Razelle Kurzrock
Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy. Molecular cancer therapeutics (2023)
Filippo de Braud, Christophe Dooms, Rebecca S Heist, Celeste Lebbè, Martin Wermke, Anas Gazzah, Dirk Schadendorf, Piotr Lukasz Rutkowski, Juergen Wolf, Paolo Antonio Ascierto, Ignacio Gil-Bazo, Shumei Kato, Maria Wolodarski, Meredith A McKean, Eva Muñoz Couselo, Martin Sebastian, Armando Santoro, Vesselina Cooke, Luca Manganelli, Kitty Wan, Anil Gaur, Jaeyeon Kim, Giordano Caponigro, Xuân-Mai Couillebault, Helen Evans, Catarina D Campbell, Sumit Basu, Michele Moschetta, Adil I Daud
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS -Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Shai Rosenberg, Gil Ben Cohen, Shumei Kato, Ryosuke Okamura, Scott M Lippman, Razelle Kurzrock
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. Molecular oncology (2023)
Akram Mesleh Shayeb, Razelle Kurzrock, Jacob J Adashek, Shumei Kato
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies. JCO precision oncology 7 (2023)
Lindsey M Charo, Ramez N Eskander, Jason K Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Suzanna Lee, Rupa Subramanian, Richard B Schwab, Rebecca Shatsky, Steven Plaxe, Shumei Kato, Razelle Kurzrock
Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO precision oncology 6 (2022)
Steven B Maron, Stephanie Moya, Federica Morano, Matthew J Emmett, Joanne F Chou, Shalom Sabwa, Henry S Walch, Bryan Peterson, Alexa B Schrock, Liangliang Zhang, Yelena Y Janjigian, Sree Chalasani, Geoffrey Y Ku, Umut Disel, Peter Enzinger, Nataliya Uboha, Shumei Kato, Takayuki Yoshino, Kohei Shitara, Yoshiaki Nakamura, Anwaar Saeed, Pashtoon Murtaza Kasi, Joseph Chao, Jeeyun Lee, Marinela Capanu, Zev A Wainberg, Russell Petty, Filippo Pietrantonio, Samuel J Klempner, Daniel V T Catenacci
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (22) (2022)
Farshid Dayyani, Shumei Kato, Razelle Kurzrock
Hyperprogression in Gastric Cancer: Is MDM2 Amplification the Dark Horse? JCO precision oncology 5 (2022)
Bryan H Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Suzanna Lee, Ryosuke Okamura, Paul T Fanta, Razelle Kurzrock
Precision medicine-based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience. Molecular oncology 16 (13) (2022)
Betzaira G Childers, Divya Sood, Rohini Patel, Evangeline S Mose, Mojgan Hosseini, Shumei Kato, Joel M Baumgartner, Andrew M Lowy
Palbociclib as a Novel Therapy for Low-Grade Mucinous Carcinomatosis Peritonei of Appendiceal Origin. JCO precision oncology 5 (2022)
Shumei Kato, Sophia Gumas, Jacob J Adashek, Ryosuke Okamura, Suzanna Lee, Jason K Sicklick, Razelle Kurzrock
Multi-omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown. Molecular oncology (2022)
Shumei Kato, Caroline Weipert, Sophia Gumas, Ryosuke Okamura, Suzanna Lee, Jason K Sicklick, Jennifer Saam, Razelle Kurzrock
Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO precision oncology 5 (2021)
Ryosuke Okamura, David E Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick, Shumei Kato, Razelle Kurzrock
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. International journal of cancer 148 (11) (2021)
Sandy S Bohan, Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Vincent A Miller, Brian Leyland-Jones, Scott M Lippman, Razelle Kurzrock
Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. The oncologist 25 (11) (2020)
Filip Janku, Divya Sakamuri, Shumei Kato, Helen J Huang, S Greg Call, Aung Naing, Veronica R Holley, Sapna Pradyuman Patel, Rodabe N Amaria, Gerald S Falchook, Sarina A Piha-Paul, Ralph G Zinner, Apostolia-Maria Tsimberidou, David S Hong, Funda Meric-Bernstam
Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer 127 (3) (2020)
Ryosuke Okamura, Razelle Kurzrock, Robert J Mallory, Paul T Fanta, Adam M Burgoyne, Bryan M Clary, Shumei Kato, Jason K Sicklick
Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers. International journal of cancer 148 (3) (2020)
Shumei Kato, Ryosuke Okamura, Jason K Sicklick, Gregory A Daniels, David S Hong, Aaron Goodman, Elizabeth Weihe, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Paul Riviere, Theresa J Whitchurch, Paul T Fanta, Scott M Lippman, Razelle Kurzrock
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. International journal of cancer 146 (12) (2020)
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amelie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis John Kuo, Ramez N Eskander, Aaron Goodman, Natalie Galanina, Paul T Fanta, Richard B Schwab, Rebecca Shatsky, Steven C Plaxe, Andrew Sharabi, Edward Cooper Stites, Jacob J Adashek, Ryosuke Okamura, Suzanna Lee, Scott M Lippman, Jason K Sicklick, Razelle Kurzrock
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nature communications 11 (1) (2020)
Kristina Mardinian, Ryosuke Okamura, Shumei Kato, Razelle Kurzrock
Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. International journal of cancer 146 (2) (2019)
Minny Bhatty, Shumei Kato, Sarina A Piha-Paul, Aung Naing, Vivek Subbiah, Helen J Huang, Daniel D Karp, Apostolia M Tsimberidou, Ralph G Zinner, Wen-Jen Hwu, Milind M Javle, Sapna P Patel, Mimi I Hu, Gauri R Varadhachary, Anthony P Conley, Nishma M Ramzanali, Veronica R Holley, Razelle Kurzrock, Funda Meric-Bernstam, Young Kwang Chae, Kevin B Kim, Gerald S Falchook, Filip Janku
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. Cancer 125 (3) (2018)